3PBiovian
3PBIOVIAN is a pan-European biologics CDMO offering end-to-end contract development and manufacturing services — proteins, viral vectors, plasmid DNA, cell therapies, and fill & finish — to biotech and pharmaceutical companies from clinical through commercial stages.
- Company typePrivate
- Founded2007
- HeadquartersNoáin, Spain
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What 3PBiovian does
3PBIOVIAN is a pan-European Contract Development and Manufacturing Organization (CDMO) headquartered in Noáin (Pamplona), Spain, formed through the 2024 combination of 3P Biopharmaceuticals (Spain, founded 2007 by Dámaso Molero) and Biovian Oy (Finland). The company delivers end-to-end biologics and advanced therapy manufacturing services to biotech and pharmaceutical clients globally, operating dual GMP-licensed manufacturing sites in Pamplona-Noáin, Spain and Turku, Finland. 3PBIOVIAN is majority-owned by private equity firm Keensight Capital, with President Amit Karna also serving as a Keensight partner.
The service portfolio spans four core platforms — recombinant proteins (microbial and mammalian expression systems), viral vectors (AAV and adenovirus), plasmid DNA, and cell therapies — supplemented by aseptic fill & finish, QC services, and conjugated biotherapeutics manufacturing (including ADCs, radio-immunoconjugates, and pegylation). Mammalian GMP capacity extends from 50 L to 2,000 L following the installation of a second 2,000 L single-use bioreactor in May 2026. Proprietary technology includes the AAVion® Design-of-Experiments-optimized AAV manufacturing platform and in-house Freedom-to-Operate (FTO) plasmid manufacturing that allows gene therapy clients to operate globally without third-party IP constraints. The company holds EMA GMP licensing and FDA establishment registration for microbiological testing, enabling transatlantic clinical and commercial supply, and a French CIR certification for 2025–2027.
3PBIOVIAN operates a B2B enterprise sales motion, generating revenue through project-based contract manufacturing engagements spanning early-stage development through commercial supply. The pre-rebrand 2022 revenue base was approximately €35 million (3P Biopharmaceuticals Spain-only), with more than 60 customers served across 20 countries and over 75 molecules developed commercially. Capital intensity is significant, with disclosed investments exceeding €50 million in the Turku facility (2023) plus ongoing capacity expansion in Spain. The customer base disclosed consists primarily of clinical-stage biotechs developing gene therapies, recombinant biologics, vaccines, and radiopharmaceuticals, with no large-cap pharma anchor customers visible in available material.
3PBiovian firmographics
Firmographics- Name
- 3PBiovian
- Legal name
- 3P BIOPHARMACEUTICALS, S.L.U.
- Website
- https://3pbiovian.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- 3PBIOVIAN is a pan-European biologics CDMO offering end-to-end contract development and manufacturing services — proteins, viral vectors, plasmid DNA, cell therapies, and fill & finish — to biotech and pharmaceutical companies from clinical through commercial stages.
- Ownership category
- akta.pro rank
3PBiovian industry classification
Industry- Product category
- Biologics Contract Manufacturing (CDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
Keywords
Where 3PBiovian is headquartered
LocationHeadquarters
- HQ city
- Noáin
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
3PBiovian business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Services: Full-range biopharmaceutical manufacturing services covering process development, analytical testing, clinical production, and large-scale commercial manufacturing. Revenue generated through project-based contracts for biotech and pharma companies from early-stage development through commercialization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based contract manufacturing pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
3PBiovian product offering
Product offeringCore offering
3PBIOVIAN is a global CDMO providing end-to-end contract development and manufacturing services for biologics and advanced therapies across the full product lifecycle — from early-stage process development and analytical method validation through clinical production to large-scale commercial manufacturing. Core offerings span recombinant proteins (microbial and mammalian), viral vectors (AAV and adenovirus) including the proprietary AAVion® platform, plasmid DNA at RG/HQ/GMP grades, cell therapies, aseptic fill & finish, QC services, and conjugated biotherapeutics, delivered from two GMP-certified manufacturing sites in Pamplona, Spain and Turku, Finland.
Product overview
3PBIOVIAN is a pan-European Contract Development and Manufacturing Organization (CDMO) offering integrated, end-to-end biologics and advanced therapy manufacturing services from early development through clinical supply and commercial manufacturing. The company operates GMP manufacturing sites in Pamplona, Spain and Turku, Finland. Its core portfolio spans four major service areas: (1) Proteins – including Microbial Proteins and Mammalian Proteins (with capacities from 50 L to 2,000 L), (2) Viral Vectors – covering AAV Manufacturing with the proprietary AAVion® Platform, Adenovirus Manufacturing, and related technologies, (3) Plasmid DNA – available in Research-grade, High-Quality, and GMP-grade qualities including Freedom-to-Operate (FTO) plasmids, and (4) Cell Therapies. Supporting services include Aseptic Fill & Finish (with dedicated BSL1/BSL2 filling lines), QC Services (compendial analysis, sterility testing, bioburden, endotoxin), and Conjugated Biotherapeutics (ADC's, antibody-oligonucleotide conjugates, pegylation, nanoparticles). The company supports the full product lifecycle from pre-clinical through Phase I, II, III, and commercial manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- Recombinant Proteins (Microbial & Mammalian) Recombinant protein manufacturing services using both microbial (E. coli) and mammalian cell culture expression platforms, covering process development, analytical testing, clinical production, and large-scale commercial manufacturing. Mammalian GMP capacity ranges from 50 L to 2,000 L with a second 2,000 L bioreactor. Microbial fermentation capacity includes a 500 L fermenter.
- Viral Vector Manufacturing (AAV and Adenovirus) Viral vector manufacturing services for gene therapy and vaccine development. AAV manufacturing uses HEK293 cells with transient transfection via the proprietary DoE-optimized AAVion® platform. Adenovirus manufacturing uses suspension cell cultures. Serves gene therapy and vaccine developers from preclinical through commercial scale.
- Plasmid DNA Manufacturing Plasmid DNA CDMO services for preclinical, clinical, and commercial production under GMP standards. Available in Research-grade, High-Quality, and GMP-grade qualities. Includes proprietary Freedom-to-Operate (FTO) plasmids free from third-party IP constraints, enabling global drug development programs and seamless transfer across manufacturing sites.
- Cell Therapy Development and Manufacturing Comprehensive cell therapy development and manufacturing services to accelerate the development, manufacturing, and commercialization of advanced therapies, supporting the full lifecycle from pre-clinical through commercial manufacturing.
- Aseptic Fill & Finish Integrated Fill & Finish service chain including formulation, aseptic Fill & Finish, terminal sterilization or aseptic processing, visual inspection, in-house sterility testing, labeling, packaging, and Qualified Person certified release. Operates dedicated filling lines for BSL1 and BSL2 products.
- Quality Control (QC) Services Comprehensive quality control services including physico-chemical, microbiological, and functional assays, compendial analysis (Ph.Eur. and USP), product-specific validation, sterility testing, bioburden, and endotoxin testing under GMP standards. FDA-inspected microbiological testing laboratory.
- Conjugated Biotherapeutics Manufacturing Conjugated biologics development and manufacturing services including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates, radio-immunoconjugates, pegylation, and nanoparticle conjugation technologies.
Quantifiable outcome
- Reduced batch failure risk through integrated in-house analytics
- +2 more outcomes
Companies that use 3PBiovian
Customer profileNamed customers10 records
Segments2 records
Ideal customer profiles2 records
3PBiovian technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability4 records
Feature3 records
3PBiovian partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered strategic, core, client and industry.
- INC (International Neighborhood Corporation)strategicPartnership to expand access to oncology treatments in Colombia through biosimilar development.
- Universidad CEU San PablocoreBusiness Collaboration Agreement for promoting academic excellence, talent development, and scientific knowledge advancement. Includes annual financial contribution to San Pablo-CEU University Foundation for TFG/TFM awards, and creation of Aula 3PBIOVIAN collaborative classroom space.
- Public University of Navarre (UPNA)coreCollaboration on micro-credentials programme for lifelong learning, professional upskilling, and industry-academia collaboration. 3PBIOVIAN contributed to development of two micro-credentials delivered across six editions, with approximately 160 employees participating.
- ANLBIOclientANLBIO selected Biovian for manufacturing of AAV-based product for the treatment of Alzheimer's disease.
- Zhittyaclient3P Biopharmaceuticals continues collaboration with U.S. biotech Zhittya for the treatment of Parkinson's disease.
- Toleranzia ABclientSuccessful ongoing collaboration with Toleranzia AB to fight Myasthenia Gravis.
- Precirix NVclientAlliance for clinical manufacturing of camelid single-domain antibody fragment (sdAb) backbone for precision radiopharmaceuticals in oncology.
- Lokon Pharma ABclientAgreement signed with Lokon Pharma AB for manufacturing of clinical programs.
- Buzzard PharmaceuticalsclientPartnership for cGMP manufacturing of Isunakinra, a potent recombinant protein IL-1 inhibitor for cancer indications.
- BiosergenclientCompleted manufacture of biomass for Mucormycosis (Black Fungus) clinical phase II trial.
- BrainEverclientCollaboration on development of recombinant human homeoprotein Engrailed-1.
- OsivaxclientCollaboration to develop a new universal vaccine against current and future variants of SARS-CoV-2.
- Swedish Bioindustries (FIB)industryAntti Nieminen from 3PBIOVIAN serves on the Finnish Bioindustries FIB board, representing the company in industry association.
Scale indicators8 records
Recent moves10 records
Expansion highlights7 records
3PBiovian competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
3PBiovian social profiles
Digital presence3PBiovian compliance and trust
Trust signalCompliance5 records
3PBiovian financial estimates
Financial estimateRevenue estimate
Valuation estimate
3PBiovian leadership team
Management profileNumber of profiles
Profiles13 records
3PBiovian funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
3PBiovian M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 3PBiovian
What does 3PBiovian do?
3PBIOVIAN is a global CDMO providing end-to-end contract development and manufacturing services for biologics and advanced therapies across the full product lifecycle — from early-stage process development and analytical method validation through clinical production to large-scale commercial manufacturing. Core offerings span recombinant proteins (microbial and mammalian), viral vectors (AAV and adenovirus) including the proprietary AAVion® platform, plasmid DNA at RG/HQ/GMP grades, cell therapies, aseptic fill & finish, QC services, and conjugated biotherapeutics, delivered from two GMP-certified manufacturing sites in Pamplona, Spain and Turku, Finland.
Is 3PBiovian a public or private company?
3PBiovian is a private company. It is classified as private equity controlled and is currently operating.
When was 3PBiovian founded?
3PBiovian was founded in 2007. It employs 501 to 1,000 people.
Where is 3PBiovian based?
3PBiovian is headquartered in Noáin, Spain, in the Europe region.
How does 3PBiovian make money?
One revenue line is on record: contract Development and Manufacturing Services.
Does 3PBiovian have an API?
No public API is recorded for 3PBiovian.
What industry is 3PBiovian in?
3PBiovian's product category is Biologics Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 8731.